| Literature DB >> 35383265 |
Seung Jae Lee1,2, Sang Ah Lee3, Seungyeon Lee1,2, Hyoung Won Bae1, Chan Yun Kim1, Gong Je Seong1, Jong Woon Park2, Kwanghyun Lee4,5.
Abstract
Despite the clinical importance of glaucoma surgery, studies on its prevalence and risk factors are limited. We analyzed a database comprising approximately 1,000,000 Korean residents to investigate the prevalence and risk factors for undergoing glaucoma surgery within 5 years of diagnosis with open-angle glaucoma. Of the 4,303 patients evaluated, 226 (5.3%) underwent glaucoma surgery. Factors associated with the likelihood of glaucoma surgery included the use of two or more eye drops (odds ratio [OR], 30.30; 95% confidence interval [CI], 10.95-83.84), intake of oral carbonic anhydrase inhibitor (OR, 1.79; 95% CI, 1.23-2.61), age > 55 years (55-65 years: OR, 1.71; 95% CI, 1.06-2.76; > 65 years: OR 1.72; 95% CI, 1.10-2.70), female sex (OR, 1.46; 95% CI, 1.10-1.94), middle- and high-income (OR, 2.36; 95% CI, 1.30-4.28, OR, 1.86; 95% CI, 1.03-3.35, respectively), and metropolitan residence (OR, 1.61; 95% CI, 1.14-2.26). Our nomogram for predicting the likelihood of glaucoma surgery showed an acceptable result. In conclusion, older age, female sex, and the intensity of intraocular pressure lowering treatment increased the likelihood of undergoing glaucoma surgery. Our findings indicated that a lower socioeconomic status may forestall receiving this necessary surgery, which requires further attention.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35383265 PMCID: PMC8983768 DOI: 10.1038/s41598-022-09832-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
General characteristics of study population.
| Variables | Total | Glaucoma operation | |||||
|---|---|---|---|---|---|---|---|
| No | Yes | ||||||
| (%) | (%) | (%) | |||||
| None | 817 | 19.0 | 813 | 99.5 | 4 | 0.5 | |
| PG | 1296 | 30.1 | 1243 | 95.9 | 53 | 4.1 | |
| Non-PG | 1508 | 35.1 | 1440 | 95.5 | 68 | 4.5 | |
| Two or more | 682 | 15.9 | 581 | 85.2 | 101 | 14.8 | |
| No | 3974 | 92.4 | 3796 | 95.5 | 178 | 4.5 | |
| Yes | 329 | 7.7 | 281 | 85.4 | 48 | 14.6 | |
| < 45 | 782 | 18.2 | 751 | 96.0 | 31 | 4.0 | |
| 45–54 | 775 | 18.0 | 749 | 96.7 | 26 | 3.4 | |
| 55–64 | 1049 | 24.4 | 986 | 94.0 | 63 | 6.0 | |
| 65 + | 1697 | 39.4 | 1591 | 93.8 | 106 | 6.3 | |
| 0.091 | |||||||
| Men | 1996 | 46.4 | 1904 | 95.4 | 92 | 4.6 | |
| Women | 2307 | 53.6 | 2173 | 94.2 | 134 | 5.8 | |
| 0.088 | |||||||
| Medical aids | 386 | 9.0 | 372 | 96.4 | 14 | 3.6 | |
| Low | 707 | 16.4 | 672 | 95.1 | 35 | 5.0 | |
| Middle | 1265 | 29.4 | 1183 | 93.5 | 82 | 6.5 | |
| High | 1945 | 45.2 | 1850 | 95.1 | 95 | 4.9 | |
| Capital area | 1993 | 46.3 | 1907 | 95.7 | 86 | 4.3 | |
| Metropolitan area | 974 | 22.6 | 907 | 93.1 | 67 | 6.9 | |
| Rural area | 1336 | 31.1 | 1263 | 94.5 | 73 | 5.5 | |
| 0.123 | |||||||
| No | 3836 | 89.2 | 3627 | 94.6 | 209 | 5.5 | |
| Yes | 467 | 10.9 | 450 | 96.4 | 17 | 3.6 | |
| 0.966 | |||||||
| No | 3680 | 85.5 | 3486 | 94.7 | 194 | 5.3 | |
| Yes | 623 | 14.5 | 591 | 94.9 | 32 | 5.1 | |
| 0.191 | |||||||
| No | 3484 | 81.0 | 3293 | 94.5 | 191 | 5.5 | |
| Yes | 819 | 19.0 | 784 | 95.7 | 35 | 4.3 | |
| 0.950 | |||||||
| 0 | 1948 | 45.3 | 1844 | 94.7 | 104 | 5.3 | |
| 1 | 1451 | 33.7 | 1373 | 94.6 | 78 | 5.4 | |
| 2 | 642 | 14.9 | 611 | 95.2 | 31 | 4.8 | |
| 3 + | 262 | 6.1 | 249 | 95.0 | 13 | 5.0 | |
| 4303 | 100.0 | 4077 | 94.8 | 226 | 5.3 | ||
PG: Prostaglandin analogue; CAI: Carbonic anhydrase inhibitor; Hx: History, *P-values were calculated using Chi-square test. Indicated in bold type, P < 0.05 indicates statistical significance.
Figure 1Flow diagram of study population selection. OAG: open-angle glaucoma, ACG: angle-closure glaucoma.
Results of multiple logistic regression.
| Simple Logistic regression | Multiple logistic regression | |||||||
|---|---|---|---|---|---|---|---|---|
| Odds Ratio | 95% | CI | Adjusted OR | 95% | CI | |||
| None | 1.00 | 1.00 | ||||||
| PG | 8.67 | 3.12 | 24.03 | 8.69 | 3.12 | 24.16 | ||
| Non-PG | 9.60 | 3.49 | 26.40 | 8.78 | 3.18 | 24.28 | ||
| Two or more | 35.33 | 12.93 | 96.49 | 30.30 | 10.95 | 83.84 | ||
| No | 1.00 | 1.00 | ||||||
| Yes | 3.64 | 2.59 | 5.12 | 1.79 | 1.23 | 2.61 | ||
| < 45 | 1.19 | 0.70 | 2.02 | 0.523 | 1.28 | 0.75 | 2.21 | 0.367 |
| 45–54 | 1.00 | 1.00 | ||||||
| 55–64 | 1.84 | 1.15 | 2.94 | 1.71 | 1.06 | 2.76 | ||
| 65 + | 1.92 | 1.24 | 2.97 | 1.72 | 1.10 | 2.70 | ||
| Men | 1.00 | 1.00 | ||||||
| Women | 1.28 | 0.97 | 1.68 | 0.079 | 1.46 | 1.10 | 1.94 | |
| Medical aids | 1.00 | 1.00 | ||||||
| Low | 1.38 | 0.74 | 2.61 | 0.314 | 1.81 | 0.94 | 3.46 | 0.075 |
| Middle | 1.84 | 1.03 | 3.29 | 2.36 | 1.30 | 4.28 | ||
| High | 1.36 | 0.77 | 2.42 | 0.287 | 1.86 | 1.03 | 3.35 | |
| Capital area | 1.00 | 1.00 | ||||||
| Metropolitan area | 1.64 | 1.18 | 2.28 | 1.61 | 1.14 | 2.26 | ||
| Rural area | 1.28 | 0.93 | 1.77 | 0.128 | 1.13 | 0.81 | 1.58 | 0.459 |
| No | 1.00 | |||||||
| Yes | 0.66 | 0.40 | 1.09 | 0.101 | ||||
| No | 1.00 | |||||||
| Yes | 0.97 | 0.66 | 1.43 | 0.890 | ||||
| No | 1.00 | |||||||
| Yes | 0.77 | 0.53 | 1.11 | 0.164 | ||||
| 0 | 1.00 | |||||||
| 1 | 1.01 | 0.75 | 1.36 | 0.962 | ||||
| 2 | 0.90 | 0.60 | 1.36 | 0.614 | ||||
| 3 + | 0.93 | 0.51 | 1.67 | 0.798 | ||||
CI: confidence interval; OR: odds ratio; PG: Prostaglandin analogue; CAI: Carbonic anhydrase inhibitor; Hx: History, *P-values were calculated using logistic regression. Indicated in bold type, P < 0.05 indicates statistical significance.
Figure 2Nomogram and its receiver operating characteristics (ROC) curve for predicting the likelihood for newly diagnosed open-angle glaucoma patients to undergo glaucoma surgery. (A) Nomogram from multiple logistic regression model. Find the position of each variable on the corresponding axis and draw a line to the ‘Points’ scale (top axis) to determine the number of points for each variable. Sum the points for all the variables together and draw a line from the ‘Total points’ axis to determine the likelihood of undergoing glaucoma surgery at the bottom. (B) ROC curve and its diagnostic performance. AUC: area under the curve.